23 research outputs found
The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets
Chondrosarcomas are malignant cartilage-forming tumours representing around 20% of malignant primary tumours of bone and affect mainly adults in the third to sixth decade of life. Unfortunately, the molecular pathways controlling the genesis and the growth of chondrosarcoma cells are still not fully defined. It is well admitted that the invasion of bone by tumour cells affects the balance between early bone resorption and formation and induces an “inflammatory-like” environment which establishes a dialogue between tumour cells and their environment. The bone tumour microenvironment is then described as a sanctuary that contributes to the drug resistance patterns and may control at least in part the tumour growth. The concept of “niche” defined as a specialized microenvironment that can promote the emergence of tumour stem cells and provide all the required factors for their development recently emerges in the literature. The present paper aims to summarize the main evidence sustaining the existence of a specific bone niche in the pathogenesis of chondrosarcomas
Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma
BACKGROUND: Osteosarcoma is the most common type of primary bone tumor. The use of aggressive chemotherapy has drastically improved the prognosis of the patients with non-metastatic osteosarcomas, however the prognosis of the patients with metastasis is still very poor. Then, new and more effective treatments for curing osteosarcoma, such as immunotherapy are needed. Tumor-infiltrating lymphocytes (TIL) have been involved in the control of tumor development and already assessed with success for the treatment of several cancers including melanoma. While TIL represent a fascinating therapeutic approach in numerous malignant pathologies, there is few report concerning adult bone-associated tumors including osteosarcoma. METHODS: Human TIL were isolated and characterized (phenotype, lytic activity) from twenty-seven patients with bone-associated tumors (osteosarcoma, Ewing's sarcoma, giant cell tumor, chondrosarcoma, plasmocytoma and bone metastases). Similar experiments were performed using rat osteosarcoma model. RESULTS: While TIL with a main CD4(+ )profile were easily isolated from most of the tumor samples, only TIL extracted from osteosarcoma were cytotoxic against allogeneic tumor cells. In all cases, TIL lytic activity was significantly higher compared to autologous peripheral blood leukocytes. Similar data were observed in rat osteosarcoma model where TIL were characterized by a main CD4(+ )profile and high lytic activity against allogeneic and autologous tumor cells. Moreover, rat TIL expansion was not accompanied by refractoriness to further activation stimulus mainly by tumor antigens. CONCLUSION: These results demonstrated that TIL therapy could be a very efficient strategy for the treatment of adult osteosarcoma
The identification of proteoglycans and glycosaminoglycans in archaeological human bones and teeth
Bone tissue is mineralized dense connective tissue consisting mainly of a mineral component (hydroxyapatite) and an organic matrix comprised of collagens, non-collagenous proteins and proteoglycans (PGs). Extracellular matrix proteins and PGs bind tightly to hydroxyapatite which would protect these molecules from the destructive effects of temperature and chemical agents after death. DNA and proteins have been successfully extracted from archaeological skeletons from which valuable information has been obtained; however, to date neither PGs nor glycosaminoglycan (GAG) chains have been studied in archaeological skeletons. PGs and GAGs play a major role in bone morphogenesis, homeostasis and degenerative bone disease. The ability to isolate and characterize PG and GAG content from archaeological skeletons would unveil valuable paleontological information. We therefore optimized methods for the extraction of both PGs and GAGs from archaeological human skeleto ns. PGs and GAGs were successfully extracted from both archaeological human bones and teeth, and characterized by their electrophoretic mobility in agarose gel, degradation by specific enzymes and HPLC. The GAG populations isolated were chondroitin sulfate (CS) and hyaluronic acid (HA). In addition, a CSPG was detected. The localization of CS, HA, three small leucine rich PGs (biglycan, decorin and fibromodulin) and glypican was analyzed in archaeological human bone slices. Staining patterns were different for juvenile and adult bones, whilst adolescent bones had a similar staining pattern to adult bones. The finding that significant quantities of PGs and GAGs persist in archaeological bones and teeth opens novel venues for the field of Paleontology
Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence
Background: Osteosarcoma is the most common malignant primary bone tumour in young adult treated by neo adjuvant
chemotherapy, surgical tumor removal and adjuvant multidrug chemotherapy. For correction of soft tissue defect
consecutive to surgery and/or tumor treatment, autologous fat graft has been proposed in plastic and reconstructive
surgery.
Principal Findings: We report here a case of a late local recurrence of osteosarcoma which occurred 13 years after the initial
pathology and 18 months after a lipofilling procedure. Because such recurrence was highly unexpected, we investigated the
possible relationship of tumor growth with fat injections and with mesenchymal stem/stromal cell like cells which are
largely found in fatty tissue. Results obtained in osteosarcoma pre-clinical models show that fat grafts or progenitor cells
promoted tumor growth.
Significance: These observations and results raise the question of whether autologous fat grafting is a safe reconstructive
procedure in a known post neoplasic context
Bone sarcomas: pathogenesis and new therapeutic approaches
Bone sarcomas include a very large number of tumor types belonging to the family of primary malignant bone tumors and originate from bone. Osteosarcoma, Ewing's sarcoma and chondrosarcoma are the three main sarcomas diagnosed in humans and despite their scarcity, sarcomas are characterized by a relatively high morbidity and mortality, especially in children and adolescents. Bone sarcomas exhibit highly heterogeneous histologic and molecular profiles; their morphology is one of the key aspects of their identification. With the exception of Ewing's sarcoma, which is related to a chromosomal translocation between the EWS gene and a gene from the ETS family, or to specific inherited syndromes (e.g., p53, Rb), the causes of most bone sarcomas are not fully understood. Recent published work demonstrates the key relationship between sarcoma cells and their microenvironment, opening a new era for understanding the pathogenesis of and advancing therapy for bone sarcomas, which are the focus of this Perspective
RANKL/RANK/OPG: key therapeutic target in bone oncology.
Cancer is one of the major leading causes of death all over the world. Primary and secondary bone tumors can significantly deteriorate the quality of life (QOL) and the activity of daily living (ADL) of the patients. These unwelcome diseases become a social and economic burden seriously. Thus, more effective therapies for both primary and secondary bone tumors are actually required. Bone homeostasis depends on the strictly balanced activities between bone formation by osteoblasts and bone resorption by osteoclasts. Imbalance of bone formation and resorption results in various bone diseases. Both primary and secondary bone tumors develop in the unique environment bone, it is therefore necessary to understand bone cell biology in tumoral bone environment. Recent findings strongly revealed the significant involvement of the receptor activator of nuclear factor kappaB ligand (RANKL)/RANK/osteoprotegerin (OPG) triad, the key regulators of bone remodeling in bone oncology. Indeed, RANKL/RANK blocking successfully prevented the development of bone metastases. Furthermore, some cancer cells express RANK which is involved in tumor cell migration. Thus, the regulation of this triad will be a rational, encouraged therapeutic hot spot in bone oncology. In this review, we summarize the accumulating knowledge of the RANKL/RANK/OPG triad and discuss about its therapeutic capability in primary and secondary bone tumors
Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?
Primary and secondary bone tumors clearly
deteriorate quality of life and the activity of daily living
of patients. These undesirable diseases become a major
social and economic burden. As both primary and
secondary bone tumors develop in the unique bone
tissue, it is therefore necessary to understand bone cell
biology in tumor bone environment. Recent findings of
the Receptor Activator of Nuclear Factor-kB ligand
(RANKL)/RANK/osteoprotegerin (OPG) molecular
triad, the key regulators of bone remodeling, opened new
era of bone research. Although RANK is an essential
receptor for osteoclast formation, activation and
survival, functional RANK expression has been recently
identified on several bone-associated tumor cells. When
RANK is expressed on secondary bone tumor cells, it is
implicated in tumor cell migration, whereas this is not
the case for primary bone tumors. In any case, RANK is
not involved in RANK-positive cell proliferation or
death. In two models of bone metastases secondary to
melanoma or prostate carcinoma, in vivo neutralization of RANKL by OPG resulted in complete protection from
paralysis, due to metastases of vertebral body, and a
marked reduction in tumor burden in bones, but not in
other organs. OPG also decreased tumor formation and
tumor burden in a mouse model of primary bone tumor,
osteosarcoma. In all these models, tumor cells express
RANK. These data revealed that local differentiation
factors, such as RANKL, play an important role in cell
migration in a metastatic tissue-specific manner. These
findings substantiate the novel direct role of RANKL/RANK in bone-associated tumors, and its
capability of representing new therapeutic targets
Human Rheumatoid Synovial Cells (HRSC) in Culture Express TGF-ß Receptors and are Growth Stimulated by the Factor
International audienc